Flu Vaccines for 2025-26 (United States)
Flu Vaccines for 2025-26 (United States)
For the 2025-26 influenza season, US influenza vaccines are all trivalent (two influenza A-like viruses and one influenza B-type virus).1 Current ACIP recommendation is for single-dose, thimerosal-free preparations only.2 The American Academy of Pediatrics (AAP) and WHO both continue to support the use of multi-dose vials of influenza vaccine containing thimerosal as a preservative.10 This chart reviews approved influenza vaccines for the 2025-26 season. It includes approved ages for use, route of administration, dose, cost, and egg and thimerosal content. For information about efficacy, administration with other vaccines, use in patients who are immunocompromised or pregnant, and more, see our resource, Communicating About Flu Vaccination.
--None of the available flu vaccines for 2025-26 contain latex. Information in table is from product labeling, unless otherwise noteda--
Brand Name Manufacturer |
Route |
Approved Ages for Use |
Availability (Cost/doseb) |
Contains Thimerosal?c |
Dose |
Comments |
Trivalent inactivated influenza vaccine (IIV3) |
||||||
Afluria Seqirus |
IM |
≥6 months *Administering Afluria with the PharmaJet Stratis needle-free injector is only approved for ages 18 to 64 years. |
0.5 mL PFS (~$22) 5 mL MDV (~$20) |
No (PFS) Yes (MDV) |
6 to
≥36 months:
|
|
Fluad Seqirus |
IM |
≥65 years |
0.5 mL PFS (~$79) |
No |
≥65 years:
|
|
Fluarix GSK |
IM |
≥6 months |
0.5 mL PFS (~$20) |
No |
0.5 mL |
|
Flucelvax Seqirus |
IM |
≥6 months |
0.5 mL PFS (~$43) 5 mL MDV (~$43) |
No (PFS) Yes (MDV) |
0.5 mL |
|
FluLaval GSK |
IM |
≥6 months |
0.5 mL PFS |
No |
0.5 mL |
None |
Fluzone Sanofi Pasteur |
IM |
≥6 months |
0.5 mL PFS (~$20) 5 mL MDV (~$20) |
No (PFS) Yes (MDV) |
6 to
≥36 months:
|
None |
Fluzone High-Dose Sanofi Pasteur |
IM |
≥65 years |
0.5 mL PFS (~$79) |
No |
0.5 mL |
|
Trivalent recombinant influenza vaccine (RIV3) |
||||||
Flublok Sanofi Pasteur |
IM |
≥9 years |
0.5 mL PFS (~$79) |
No |
0.5 mL |
|
Trivalent live-attenuated influenza vaccine (LAIV3) |
||||||
FluMist Intransal Spray MedImmune |
Intranasal |
2 to 49 years |
0.2 mL prefilled intranasal sprayer (~$26) |
No |
0.1 mL per nostril |
|
- Information is from product labeling, unless otherwise noted: Afluria (June 2025); Fluad (July 2025); Fluarix (July 2025); Flucelvax (July 2025); FluLaval (July 2025); Fluzone (July 2025); Fluzone High-Dose Northern Hemisphere (July 2025); Flublok Trivalent (July 2025); FluMist (July 2025).
- Pricing based on one dose at wholesale acquisition cost (WAC). Medication pricing by Elsevier, accessed August 2025.
- For more information on the safety of thimerosal, see the Children’s Hospital of Philadelphia (https://www.chop.edu/vaccine-education-center/vaccine-safety/vaccine-ingredients/thimerosal) and immunize.org (https://www.immunize.org/ask-experts/does-the-thimerosal-in-some-vaccines-pose-a-risk/).
Abbreviations: ACIP = Advisory Committee on Immunization Practices; GSK = GlaxoSmithKline; IM = intramuscular; MDV = multidose vial; PFS = pre-filled syringe; SDV = single-dose vial.
References
- American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2025–2026: Policy Statement. Pediatrics. 2025; doi: 10.1542/peds.2025-073620.
- CDC. ACIP recommendations. July 28, 2025. https://www.cdc.gov/acip/vaccine-recommendations/index.html. (Accessed August 5, 2025).
- CDC. Influenza (Flu). Who needs a flu vaccine. October 3, 2024. https://www.cdc.gov/flu/vaccines/vaccinations.html#:~:text=For%20people%20younger%20than%2065,Fluad%20adjuvanted%20inactivated%20flu%20vaccine. (Accessed August 5, 2025).
- Goldberg R. Influenza vaccines in older adults: aIIV3 more effective than HD-IIV3e and IIV4e. June 5, 2024. https://www.pulmonologyadvisor.com/news/influenza-vaccines-in-adults-65-aiiv3-vs-hd-iiv3e-vs-iiv4e/. (Accessed August 5, 2025).
- CDC. Vaccine abbreviations. July 29, 2025. https://www.cdc.gov/vaccines/hcp/vaccines-us/abbreviations.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/terms/vacc-abbrev.html. (Accessed August 5, 2025).
- DiazGranados CA, Dunning AJ, Kimmel M, et al.Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014 Aug 14;371(7):635-45.
- CDC. Influenza (flu). Key facts about seasonal flu vaccine. September 17, 2024. https://www.cdc.gov/flu/prevent/keyfacts.htm. (Accessed August 5, 2025).
- CDC. CDC updates vaccine recommendations. July 12, 2024. https://www.cdc.gov/ncird/whats-new/cdc-updates-vaccine-recommendations-july-2024.html. (Accessed August 5, 2025).
- AstraZenaca. FluMist – protection without the injection. https://www.flumisthcp.com/content/dam/physician-services/us/567-flumistquadrivalent-hcp/US-100878-(Populated%20version)-FINAL-6-26-25-Digital.pdf. (Accessed August 8, 2025).
- American Academy of Pediatrics. AAP releases 2025-26 flu vaccine recommendations; efforts to increase vaccination ‘urgently needed’. July 28, 2025. https://publications.aap.org/aapnews/news/32712/AAP-releases-2025-26-flu-vaccine-recommendations?autologincheck=redirected. (Accessed August 8, 2025).
Cite this document as follows: Clinical Resource, Flu Vaccines for 2024-25 (United States). Pharmacist’s Letter/Pharmacy Technician’s Letter/Prescriber Insights. September 2025. [410961]